ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABVX vs PRAX // DIVIDEND YIELD & FCF PAYOUT SAFETY

Abivax SA (NASDAQ) VS. Praxis Precision Medicines Inc. (NASDAQ) • 15-METRIC TALLY: ABVX 5 — PRAX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVX VS. PRAX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABVX PRAX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% -35.00% +44.90 ABVX /roic <GO>
EV/EBITDA & P/E Valuation 21.0x — — TIE /valuation <GO>
Free Cash Flow Yield 2.21% -3.09% +5.30 ABVX /fcf-yield <GO>
Operating Margin 13.90% — — TIE /operating-margins <GO>
Net Profit Margin 10.90% — — TIE /net-margins <GO>
Revenue Growth (YoY) 8.80% 8.80% 0.00 TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 26.00 -22.26 PRAX /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 ABVX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.7 56.3 -11.60 PRAX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.05 0.91 +0.14 ABVX /macro-sensitivity <GO>
Forward P/E Multiple 30.5x 33.0x -2.50 ABVX /forward-pe <GO>
Enterprise Scale & Market Cap $7.77B $8.06B -$287.4M PRAX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABVX REV PRAX REV ABVX GROSS % PRAX GROSS % ABVX FCF PRAX FCF
FY 2025 — $0 — — — -$249.1M
FY 2024 — $8.6M — — — -$131.8M
FY 2023 — $2.4M — — — -$111.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVX // BETA 1.05
PRAX // BETA 0.91